virus
oblig
intracellular
parasit
evolv
transfer
genet
materi
infect
cell
use
biosynthet
machineri
replic
encapsid
packag
genom
viru
particl
usual
secret
infect
neighbour
cell
start
new
infecti
cycl
discoveri
virus
could
also
incorpor
transmit
gene
cellular
origin
open
possibl
use
tool
genet
modifi
cell
engin
viru
vector
allow
develop
gene
vaccin
wide
rang
infecti
diseas
cancer
rel
easi
rais
effect
immun
respons
transgen
encod
viru
vector
innat
immun
system
contain
necessari
mechan
recognis
viru
particl
lead
strong
speedi
activ
viru
particl
act
natur
adjuv
howev
capac
activ
immun
system
restrict
applic
treatment
autoimmun
disord
addit
applic
correct
genet
diseas
also
limit
immunogen
transgenespecif
immun
respons
sever
limit
success
gene
therapi
howev
despit
disadvantag
viru
vector
use
establish
strong
antigenspecif
immun
suppress
achiev
express
immunosuppress
cytokin
modul
intracellular
signal
pathway
incorpor
microrna
target
evergrow
list
differ
viru
speci
use
viru
vector
amongst
extens
use
adenovirus
adenoassoci
virus
poxvirus
interestingli
belong
retrovirida
famili
possibl
within
success
retroviru
vector
base
moloney
mous
leukemia
viru
mlv
amongst
first
engin
also
first
success
appli
human
gene
therapi
correct
genet
disord
recent
year
lentivector
strongli
appear
biomedicin
altern
vector
retroviru
cousin
lentivector
devoid
viral
protein
stabli
incorpor
genom
host
cell
lead
longterm
transgen
express
addit
unlik
simpl
retrovirus
transduc
nondivid
cell
characterist
open
applic
gene
therapi
genet
target
highli
differenti
cell
neuron
dendrit
cell
retrovirida
famili
consist
spheric
nm
virus
contain
diploid
positivesens
ssrna
figur
rna
genom
complex
nucleocapsid
protein
nc
bound
revers
transcriptas
rt
integras
proteas
pr
nucleocapsid
enclos
within
protein
shell
form
capsid
protein
ca
matrix
protein
surround
intern
core
interact
virion
lipid
envelop
incorpor
viral
envelop
glycoprotein
env
env
form
tm
transmembran
su
surfac
domain
bind
cellular
receptor
mediat
virion
entri
virus
retrovirida
famili
usual
divid
two
group
simpl
moloney
mous
leukemia
viru
mlv
complex
lentivirus
retrovirus
case
genom
organis
group
similar
mani
aspect
two
group
genom
organ
end
gag
pol
env
gene
gag
encod
structur
protein
pol
encod
revers
transcriptas
integras
proteas
env
encod
viru
envelop
glycoprotein
respons
virion
entri
target
cell
enzym
requir
genom
retrotranscript
cdna
integr
virion
matur
complex
retrovirus
addit
contain
accessori
gene
regul
viral
replic
assembl
pathogenesi
addit
gene
complex
retrovirus
import
cisact
sequenc
rna
packag
signal
requir
genom
encapsid
virion
polypurin
tract
ppt
requir
revers
transcript
longtermin
repeat
ltr
contain
hiv
promot
gener
retroviru
includ
lentivirus
life
cycl
schemat
depict
figur
retroviru
virion
bind
specif
cellular
receptor
surfac
unit
env
interact
determin
cell
tissu
tropism
particular
viru
retroviru
biolog
fairli
wellknown
ident
wide
number
receptor
known
exampl
retroviru
cellular
receptor
murin
cation
amino
acid
transport
sodiumphosph
symport
differ
strain
mous
leukemia
viru
mlv
case
receptor
cell
lymphocyt
marker
coreceptor
bind
su
induc
conform
chang
env
expos
fusion
peptid
lead
fusion
virion
cell
membran
lead
releas
retroviru
core
cytoplasm
releas
trigger
reversetranscript
reaction
retroviru
genom
possibl
increas
dntp
concentr
viral
core
contain
singl
cdna
copi
doubl
strand
genom
rna
transport
nucleu
integr
host
cell
chromosom
follow
activ
integras
simpl
requir
disappear
nuclear
membran
cell
divis
complex
retrovirus
lentivirus
activ
transport
core
cell
nucleu
without
requir
mitosi
thu
retroviru
vector
transduc
cell
mitosi
lentivir
vector
transduc
cell
independ
divis
statu
characterist
make
lentivir
vector
ideal
gene
therapi
highli
differenti
postmitot
cell
cdna
integr
host
cell
chromosom
remain
proviru
proviru
transcrib
gene
ltr
use
cellular
rna
polymeras
ii
cellular
transcript
factor
proviru
also
remain
integr
cell
throughout
life
transmit
daughter
cell
follow
mitosi
follow
standard
transcript
machineri
mrna
encod
fulllength
viral
rna
also
splice
version
encod
viral
protein
produc
transport
nucleu
translat
cytoplasm
viru
particl
assembl
specif
interact
rna
genom
gaggagpol
polyprotein
rna
packag
coupl
viral
assembl
releas
cell
virion
bud
bud
take
place
cellular
membran
env
glycoprotein
also
incorpor
bud
virion
virion
releas
viral
proteas
exert
activ
gaggagpol
polyprotein
releas
structur
protein
confer
infect
newli
form
virion
histor
reason
moloney
mlv
extens
use
develop
integr
gene
vector
engin
vector
base
mlv
genom
gag
pol
env
gene
delet
includ
either
gene
interest
transcript
control
viru
ltr
express
cassett
made
promot
choic
gene
interest
gener
vector
particl
contain
transfer
vector
viral
protein
gag
pol
env
provid
tran
packag
cell
addit
sever
sequenc
requir
ci
ltr
packag
signal
also
other
involv
revers
transcript
genom
integr
cotransfect
packag
plasmid
gener
retroviruslentiviruslik
particl
packag
vector
genom
therefor
cellular
entri
integr
vector
unabl
reassembl
produc
infecti
virion
lack
gagpol
gene
thu
integr
express
gene
interest
propag
progeni
cell
scheme
depict
lentivector
engin
system
shown
figur
advantag
simpl
retroviru
vector
lack
genomeencod
viral
protein
persist
gene
express
vector
integr
also
present
import
limit
main
one
virion
instabl
rel
low
titer
inabl
transduc
quiescent
cell
final
insert
mutagenesi
interestingli
shortcom
larg
overcom
use
lentivector
mainli
develop
human
immunodefici
viru
hiv
howev
main
advantag
use
lentivector
capac
transduc
quiescent
cell
crucial
characterist
mediat
nuclear
localis
sequenc
present
integras
protein
matrix
protein
vpr
ppt
sequenc
specif
step
gener
lentivector
differ
gener
biosafeti
extens
describ
elsewher
organ
constantli
direct
contact
extens
varieti
substanc
particl
live
organ
divers
origin
mani
compris
potenti
list
pathogen
vast
major
includ
commens
bacteria
pollen
yeast
mite
mani
type
chemic
larg
innocu
therefor
first
instanc
default
immunolog
respons
antigen
toler
unrespons
addit
immun
respons
trigger
potenti
pathogenthreat
autoprotect
mechan
exist
minimis
collater
damag
loss
toler
toward
organ
compon
autoantigen
consequ
mani
key
physiolog
mechan
maintain
immunolog
toler
one
import
clonal
delet
autoreact
lymphocyt
thymu
lymphocyt
expos
cell
receptor
tcr
surfac
specif
particular
antigen
cognat
antigen
present
cell
strongli
prolifer
activ
effector
activ
exampl
cytotox
figur
howev
clonal
delet
elimin
autoreact
cell
least
cell
specif
antigen
never
present
thymu
fact
manifest
autoimmun
disord
rheumatoid
arthriti
multipl
sclerosi
diabet
toler
toward
selfantigen
lost
antigen
recognis
b
lymphocyt
exert
effector
activ
dramat
consequ
mani
autoreact
lymphocyt
high
affin
tcr
avoid
clonal
delet
differenti
natur
regulatori
cell
strongli
immunosuppress
addit
natur
treg
anoth
immunosuppress
cell
differenti
peripheri
lymphocyt
induc
treg
aris
antigen
present
tolerogen
context
mainli
provid
tolerogen
dendrit
cell
dc
tolerogen
dc
effect
target
gene
therapi
techniqu
use
retroviru
lentiviru
vector
dc
either
trigger
effect
immun
respons
suppress
acquisit
tolerogen
activ
take
place
specif
circumst
gener
term
antigen
present
immatur
dc
result
either
treg
differenti
cell
inactivationapoptosi
tolerogen
dc
usual
express
low
level
surfac
major
histocompat
molecul
mhc
ii
costimulatori
molecul
antigen
present
icam
low
surfac
express
molecul
ensur
interact
cell
antigen
present
cell
lead
cell
activ
multipl
mechan
dc
becom
tolerogen
exert
immunosuppress
mechan
resid
dc
gut
mucos
tissu
strongli
tolerogen
due
presenc
wide
rang
immunosuppress
molecul
dc
also
becom
potent
immunosuppress
recognit
microbialderiv
antigen
tolllik
receptor
lectin
ligand
immunosuppress
cytokin
gener
tolerogen
dc
secret
high
amount
immunosuppress
cytokin
antigen
present
addit
tolerogen
dc
upregul
surfac
express
inhibitori
costimulatori
molecul
inhibit
cell
activ
case
cell
inhibitori
receptor
ligand
second
ligand
specif
express
dc
macrophag
immunosuppress
capac
still
debat
famili
member
also
immunosuppress
vista
tolerogen
dc
exert
immunosuppress
activ
varieti
mechan
includ
upregul
amino
acidmetabolis
enzym
arginas
indoleamin
ido
thought
consumpt
essenti
amino
acid
tolerogen
dc
deplet
cell
clonal
expans
arrest
becom
inactiv
capac
dc
captur
virus
transduc
retroviru
lentivirus
taken
advantag
genet
modifi
howev
two
main
problem
overcom
effici
human
dc
modif
firstli
monocytederiv
dc
particularli
difficult
transduc
possess
intracellular
restrict
factor
lentiviru
infect
secondli
process
dc
transduct
viral
vector
induc
phenotyp
function
matur
particularli
high
multipl
transduct
use
strong
obstacl
overcom
toler
achiev
two
problem
circumv
incorpor
simian
immunodefici
viru
siv
vpx
lentivector
capsid
product
vpx
counteract
human
dc
restrict
lentivector
transduct
result
use
lower
number
particl
achiev
effici
dc
modif
howev
correctli
har
immunosuppress
capac
tolerogen
dc
exploit
induc
therapeut
immunolog
toler
particularli
lentivector
especi
suitabl
modifi
dc
render
tolerogen
lentivector
introduc
gene
immunosuppress
properti
simultan
coexpress
antigen
interest
lentivector
transduct
lead
stabl
genom
integr
longlast
transgen
express
last
properti
particularli
import
induc
tolerogen
dc
differenti
prolong
antigen
present
cell
final
fulllength
transgen
express
requir
previous
identifi
specif
epitop
particular
mhc
allel
thu
lentivector
vaccin
could
readili
appli
patient
without
need
mhc
type
straightforward
procedur
differenti
tolerogen
dc
deliveri
potent
immunosuppress
cytokin
figur
retrovir
adenovir
vector
success
use
treatment
inflammatori
diseas
case
constitut
express
use
adenoviru
vector
lead
inhibit
immun
respons
prolong
dc
surviv
likewis
constitut
express
modifi
dc
inhibit
collageninduc
arthriti
mous
model
retrovir
deliveri
viral
dc
natur
encod
epsteinbar
viru
strongli
inhibit
abil
stimul
cell
vitro
similarli
retrovir
transduct
lentivector
also
use
express
dc
could
effici
inhibit
ovadepend
model
experiment
asthma
mice
modifi
dc
expand
treg
interestingli
express
host
treg
requir
establish
toler
rather
express
dc
apart
express
immunosuppress
cytokin
tolerogen
dc
differenti
target
specif
intracellular
signal
pathway
figur
well
known
mitogen
activ
protein
kinas
mapk
extracellularli
regul
kinas
erk
activ
dc
strongli
immunosuppress
fact
sustain
mapk
erk
activ
achiev
express
constitut
activ
form
upstream
mapk
lentivector
deliveri
constitut
activ
mutant
dc
result
immatur
dc
downmodul
express
bioactiv
erkactiv
dc
differenti
antigenspecif
treg
vitro
vivo
treg
strongli
expand
vivo
second
antigen
encount
inflammatori
condit
reinforc
antigenspecif
toler
control
inflammatori
arthriti
mous
model
intracellular
signal
pathway
also
exploit
induc
antigenspecif
toler
also
case
constitut
activ
type
ifn
signal
pathway
dc
lentivector
express
constitut
activ
mutant
induc
express
modifi
dc
possibl
interact
tlr
adaptor
molecul
modifi
dc
also
expand
antigenspecif
treg
vivo
inhibit
effector
cell
surpris
type
interferon
pathway
immunosuppress
certain
context
secret
share
common
signal
transduct
pathway
thu
administ
patient
multipl
sclerosi
interestingli
direct
lentivector
vaccin
achiev
vivo
transduct
suffici
number
dc
induc
toler
effect
least
one
month
potenti
drawback
strategi
limit
lifespan
transduc
dc
howev
overcom
intraven
administr
lentivector
transduc
dc
precursor
present
tissu
lead
longterm
transgen
express
anoth
strategi
base
modif
intracellular
signal
inhibit
proinflammatori
signal
pathway
figur
way
inhibit
circumst
induc
toler
classic
exampl
inhibit
pathway
wellknown
proinflammatori
rout
consequ
relb
silenc
specif
shrna
prevent
dc
matur
tlr
stimul
strategi
success
use
treatment
autoimmun
myasthenia
gravi
mice
convers
target
activ
endogen
neg
feedback
mechan
proinflammatori
pathway
also
exploit
suppressor
cytokin
signal
overexpress
dc
modifi
dc
exhibit
impair
proinflammatori
signal
modifi
dc
show
markedli
reduc
express
classic
proinflammatori
cytokin
also
show
enhanc
secret
overal
express
dc
could
effect
inhibit
experiment
autoimmun
encephalomyel
eae
mice
model
human
multipl
sclerosi
case
pathogen
antigen
lead
autoimmun
diseas
unknown
human
clearli
case
rheumatoid
arthriti
even
lentivector
also
use
suppress
autoimmun
disord
without
direct
target
pathogen
antigen
therefor
administr
b
cell
activ
factor
baff
specif
sirna
inflam
joint
suffici
treat
experiment
collageninduc
arthriti
lentivector
preferenti
transduc
dc
inflam
joint
without
need
modifi
tropism
vivo
express
baff
sirna
interf
dc
matur
inhibit
differenti
retrovir
modif
cell
also
perform
achiev
toler
diseas
unknown
uncharacteris
pathogen
antigen
exampl
introduct
ovaspecif
tcr
treg
retrovir
transduct
modifi
specif
toward
ova
administr
ova
inflam
joint
model
inflammatori
arthriti
mice
ovatreg
cell
adopt
transfer
allow
suppress
inflamm
bone
destruct
circumv
need
target
pathogen
arthritogen
antigen
similar
fashion
ovaspecif
treg
gener
erkactiv
lentivector
transduct
ovaexpress
dc
achiev
end
lentivector
also
deliv
wide
rang
immunosuppress
mediat
vasointestin
peptid
vip
vip
express
lentivectortransduc
dc
effect
inhibit
dc
matur
result
express
inhibit
immunosuppress
proinflammatori
cytokin
respect
therapeut
efficaci
mediat
differenti
expans
treg
basic
strategi
success
use
treatment
eae
coecal
ligat
punctur
clp
model
multipl
sclerosi
sepsi
human
respect
even
viral
protein
immunosuppress
properti
express
lentivector
induc
toler
major
problem
lentivector
gene
therapi
direct
administr
vivo
rais
strong
transgenespecif
immun
respons
desir
boost
immun
treatment
infecti
diseas
cancer
howev
properti
lentivir
vector
detriment
gene
therapi
genet
metabol
disord
transgenespecif
immun
respons
limit
surviv
correct
cell
therefor
therapeut
activ
eleg
strategi
prevent
trangenespecif
immun
respons
achiev
mirna
tag
figur
microrna
mirna
compris
collect
noncod
rna
form
part
posttranscript
regulatori
system
gene
express
mirna
contain
small
sequenc
nt
term
sirna
partial
complementari
endogen
mrna
sirna
inhibit
gene
express
mainli
exclus
induc
mrna
degrad
endogen
regulatori
system
also
exploit
prevent
immun
attack
genet
correct
cell
use
lentivir
vector
gene
carri
shown
transgen
express
profession
antigen
present
cell
respons
antigenspecif
cell
respons
cell
exert
cytotox
activ
toward
transgeneexpress
cell
therefor
avoid
cell
respons
express
transgen
prevent
specif
profession
antigen
present
cell
introduc
sequenc
target
haematopoieticspecif
mirna
transgen
thu
mrna
code
transgen
would
degrad
cell
hematopoiet
lineag
lymphocyt
granulocyt
macrophag
dc
cell
lineag
lentivector
could
intraven
administ
without
rais
transgenespecif
immun
respons
lead
longterm
transgen
express
hepatocyt
rather
immunolog
silenc
strategi
induc
transgenespecif
toler
expans
treg
author
studi
show
transgen
express
hepatocyt
requir
expand
treg
mirna
effect
use
express
factor
ix
liver
lead
correct
experiment
haemophilia
b
biosafeti
consider
clearli
prioriti
appli
new
experiment
therapi
human
disord
may
tackl
use
convent
approach
case
autoimmuneinflammatori
disord
rheumatoid
arthriti
diabet
biosafeti
concern
use
retroviru
lentiviru
vector
particularli
highlight
first
clinic
applic
mlvbase
retroviru
vector
treatment
xlink
scid
chronic
granulomat
diseas
case
xscid
trial
signific
number
treat
children
develop
leukemia
possibl
link
insert
mutagenesi
transcript
upregul
protooncogen
remov
provir
ltr
partial
solv
problem
selfinactiv
lentivector
sinc
viral
enhanc
contain
strongli
upregul
protooncogen
also
lead
aberr
transcript
altern
splice
genotox
effect
could
also
prevent
least
induct
toler
use
nonintegr
lentivector
nilv
lentivector
gener
straightforwardli
introduc
inactiv
mutat
integras
code
region
integrasebind
site
transfer
vector
consequ
vector
remain
nucleu
episom
longterm
express
achiev
nondivid
cell
suitabl
dc
genet
modif
nilv
shown
effect
gene
modif
retina
muscl
brain
alreadi
use
vaccin
genotox
effect
possibl
sever
poorli
differenti
cell
rather
termin
differenti
postmitot
cell
therefor
anoth
way
increas
biosafeti
physic
target
lentivector
particl
desir
celltissu
achiev
pseudotyp
retroviruslentiviru
vector
particl
envelop
glycoprotein
env
present
particl
surfac
determin
specif
recognit
target
cell
env
bind
appropri
cellular
receptor
vector
particl
gain
entri
cell
retroviru
lentiviru
vector
acquir
larg
number
differ
envelop
glycoprotein
bud
cellular
membran
produc
cell
interestingli
viral
particl
exhibit
natur
tropism
confer
incorpor
glycoprotein
use
envelop
glycoprotein
lentivector
pseudotyp
vesicular
stomat
viru
glycoprotein
vsvg
pseudotyp
vsvg
present
mani
advantag
includ
particl
stabil
high
titer
vector
prepar
importantli
vsvg
confer
viru
vector
particl
broad
host
cell
rang
includ
mous
human
dc
therefor
potenti
restrict
lentivector
tropism
may
result
safer
vivo
gene
deliveri
enhanc
therapeut
effect
reduct
lentivector
dose
retrovir
lentivir
vector
success
pseudotyp
wide
rang
differ
heterolog
viral
protein
exampl
mous
leukemia
viru
amphotrop
mlva
gibbon
ape
leukemia
viru
galv
felin
endogen
retroviru
envelop
lentivector
pseudotyp
alphaviru
envelop
confer
specif
tropism
toward
mous
human
dc
interestingli
baculoviru
confer
transduct
capac
hepatocyt
cell
immun
system
properti
exploit
induct
immunolog
toler
properti
exploit
prevent
transgenespecif
immun
respons
pseudotyp
measl
viru
hf
env
envelop
glycoprotein
confer
transduct
capac
rest
human
b
cell
possibl
target
immun
cell
type
induct
toler
addit
lentivector
also
pseudotyp
modifi
viral
glycoprotein
confer
new
tropism
vector
particl
exampl
specif
gene
target
vivo
dc
success
accomplish
introduc
select
mutat
sindbi
viru
envelop
protein
enhanc
bind
dcsign
sinc
retrovir
vector
proven
effici
system
deliv
gene
interest
target
cell
use
gene
therapi
develop
gene
vaccin
make
good
system
devoid
viral
protein
stabli
incorpor
target
cell
lentivir
vector
develop
complex
retrovirus
properti
overcom
sever
limit
simpl
retrovir
vector
includ
higher
virion
stabil
titer
lower
frequenc
insert
mutagenesi
especi
import
immunotherapi
fact
transduc
highli
differenti
cell
dc
dc
transduct
retrovir
vector
caus
phenotyp
function
matur
advantag
treat
infecti
diseas
cancer
advers
effect
immunolog
toler
desir
outcom
case
treatment
autoimmun
lentivector
deliv
immunosuppress
mediat
inhibit
matur
transduc
dc
could
design
induc
toler
hand
differ
type
matur
dc
induc
immun
respons
tolerogen
dc
peripheri
provid
tolerogen
signal
autoreact
cell
highaffin
tcr
caus
differenti
induc
treg
tolerogen
dc
use
achiev
immunolog
toler
differenti
tolerogen
dc
three
gener
use
method
deliveri
potent
immunosuppress
cytokin
target
intracellular
signal
pathway
lead
tolerogen
phenotyp
mapkerk
activ
inhibit
proinflammatori
signal
pathway
pathway
make
lentivector
transduct
dc
especi
eleg
method
fact
appli
without
previou
mhc
type
dc
automat
present
antigen
transgen
combin
deliv
immunosuppress
properti
coexpress
antigen
interest
prime
tolerogen
respons
toward
antigen
gene
therapi
lentivector
promis
limit
success
due
fact
vector
induc
strong
transgenespecif
immun
respons
vivo
limit
surviv
correct
cell
therapeut
activ
overcom
hurdl
mirna
tag
could
exploit
prevent
transgen
express
profession
antigen
present
cell
introduc
sequenc
target
specif
mirna
present
cell
certain
matur
stage
use
retrovir
vector
would
principl
seem
suitabl
diseas
immun
system
need
boost
cancer
due
eleg
immun
system
induc
immun
toler
modul
use
gene
therapi
approach
may
prove
effect
system
counter
overprotect
reaction
immun
system
may
give
rise
autoimmun
diseas
